Opportunistic Expansion OdySight is already CE marked and prescribed to 15,000 patients, with current availability in France, Spain, Belgium and the US. The company has ongoing international distribution potential, especially in markets with strong ophthalmology digital health adoption, representing a clear path for expanding hospital networks, specialty clinics, and national health system integrations.

Strategic Partnerships Past and ongoing partnerships with Novartis and distribution deals with big pharma signal openness to collaboration with global healthcare players. Leverage these relationships to pursue co-development, reimbursement pilots, and broader adoption through pharma-led care pathways and data capture initiatives.

Financial Momentum Recent funding rounds totaling around €10–10.6 million and a total funding of $21 million demonstrate investor confidence and capital available for growth initiatives such as scaling sales teams, clinical studies, and regulatory expansions in new regions.

Clinical Validation As a clinically tested mobile app for remote vision monitoring, Tilak Healthcare’s product aligns with value-based care and remote patient management. Opportunities exist to position OdySight within reimbursement pilots, national health system adoption programs, and payer-led outcomes demonstrations.

Product Maturity With a multi-language CE-marked app and a clear focus on chronic ophthalmic conditions, there is upsell potential to add modules or complementary analytics, integrate with electronic health records, and expand into neighboring ocular diseases or monitoring scenarios to broaden hospital and clinic adoption.